A flutter of briefs is landing at the U.S. District Court for the District of Columbia as hospitals square off against the pharmaceutical industry’s efforts to limit sales of discounted orphan drugs to 340B providers.
You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register. Already registered? Click here to login. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)